MacroGenics is a biopharmaceutical company developing monoclonal antibody-based therapeutics for cancer. The company emphasizes discovery, development, manufacturing, and commercialization of antibody platforms.
MacroGenics faces critical 2026 milestones for its ADC pipeline, including Phase 1 data for MGC026 and regulatory resolution for lorigerlimab. The company has financial runway through 2027 and plans IND submission for MGC030 in Q3 2026. Key investor events include ASCO abstract releases and financial results in Q2 2026.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07565155 |
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency |
NOT_YET_RECRUITING | PHASE2 |
| NCT07223567 |
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer |
WITHDRAWN | PHASE2 |
| NCT07071961 |
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] |
SUSPENDED | PHASE2 |
| NCT06730347 |
A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
RECRUITING | PHASE2 |
| NCT06723236 |
A Study of MGC028 in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06242470 |
A Study of MGC026 in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06227546 |
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06014255 |
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer |
RECRUITING | PHASE2 |
| NCT05848011 |
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer |
COMPLETED | PHASE2 |
| NCT05551117 |
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors |
TERMINATED | PHASE2 |
